openPR Logo
Press release

Cytocentrics receives GLP certification

04-14-2008 01:21 PM CET | Science & Education

Press release from: Cytocentrics AG

The Ministry for Health and Social Affairs of the state of Mecklenburg-Vorpommern awarded Cytocentrics AG the GLP certificate (Good Laboratory Practice) category 9 on 3rd of April. The Rostock-based biotechnology company is the first company in the new federal states of Germany with the authorization to carry out safety pharmacological tests on human ion channels in accordance with nationally and internationally recognized GLP guidelines.
Cytocentrics’ customers are pharmaceutical companies that wish to avoid undesired side effects of pharmaceutical ingredients with human ion channels. This type of testing is required by the EMEA, the European regulatory authority for pharmaceutical drugs as well as its US counterpart, the FDA. These authorities’ regulations stipulate that all non-clinical trials must be carried out under the GLP guidelines. “This serves to clarify side effects of substances before they are administered to people”, explained Dr. Thomas Knott, board member and founder of Cytocentrics AG.
Cytocentrics AG is now authorized to perform one part of this pre-clinical testing specific for the effects of pharmaceutical substances on human ion channels as a service provider. “One unique aspect of our certification is that our automated patch clamp technology, called CytoPatch™, has been approved in addition to the conventional patch clamp method. This technology has been in-house at Cytocentrics,” commented Dr. Knott.

GLP is a quality assurance system which governs the planning, carrying out and monitoring of non-clinical safety tests. The strict GLP standard was originally introduced to enable mutual acceptance of the results of studies performed by different laboratories in different countries. The carrying out of studies, as well as the documentation and archiving of the resulting data are strictly regulated. The quality system also has strict requirements concerning employee training and technical equipment. Authorities carry out regular audits of companies to verify the implementation of the GLP quality standard.

Cytocentrics AG
Dr. Christa Nutzhorn
Joachim-Jungius-Str. 9
18059 Rostock
Germany

Tel: +49(0)381 4059-640
E-mail: info@cytocentrics.com

Cytocentrics AG is a biotechnology company applying its ion channel expertise to support the pharmaceutical industry in the drug discovery process. The products are designed to simplify and optimize laboratory productivity. Cytocentrics want to make the drug discovery process more efficient and cost effective while focusing on quality and reliability.
The contribution is to provide cutting-edge solutions to assist drug screening of ion channel targets, especially in early drug profiling and safety pharmacology.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Cytocentrics receives GLP certification here

News-ID: 41985 • Views: 1421

More Releases from Cytocentrics AG

CCS Cell Culture Service GmbH and Cytocentrics AG agree cooperation in the field …
The Biotechnology companies CCS Cell Culture Service GmbH and Cytocentrics AG today announced the signing of a research and license agreement. The aim of the cooperation is to develop electrophysiologically optimized ion channel cell lines which allow a reliable testing of substances and drugs.The pharmaceutical industry depends on suitable in-vitro test methods for preclinical drug screening and safety pharmacology testing. Over recent years the automated patch clamp technology has established
Constant cell quality in compliance with high standards in safety pharmacology
The CytoPAQ™ Instant Cells Kit replaces time consuming and costly cell cultivation. This innovative system, developed by Cytocentrics AG, consists of certified HEK 293 cells stably transfected with hERG (human ether-a-go-go related gene)channel, intracellular and extracellular solution, and Cell Reservoir (optional accessory). CytoPAQ™ is a validated system in regards to PAQ (Performance, Accuracy and Quality) and lays the foundation for reliable and reproducible data generation.The Instant Cells are ready to

More Releases for GLP

Glucagon-Like Peptide-1 (Glp-1) Analogs Market Outlook, and Opportunity Analysis …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
In safe hands with the GLP checklist
The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks. The values of transparency, traceability, assignment of responsibilities, and safekeeping are
Glucagon-Like Peptide-1 (Glp-1) Analogs Market : Deep Analysis by Production Ove …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Glucagon-Like Peptide-1 (Glp-1) Analogs Market - Global Industry Insights - 2025
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
The Global Report Focuses on Glucagon Like Peptide-1 (GLP-1) Agonists Market 201 …
"The Report Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report is a professional and in-depth study on the current state of the Glucagon like peptide-1 (GLP-1) agonists industry. The report provides a basic overview of the industry including definitions, classifications, applications and
Sysmex Europe and GLP Systems to attend Euromedlab
Norderstedt, Germany, 21 May 2013 – Healthcare solution specialist Sysmex Europe and lab automation experts GLP Systems recently announced their long-term cooperation in the field of laboratory automation. Now both companies are attending Euromedlab in Milan from 19-23 May – and are looking forward to answering any queries. With a brand new transport concept, modular solutions and real freedom from manufacturers, they are confident they are introducing a game changer